Agenda
ATMP Sweden 2026 brings academia, healthcare and industry together around a single question: what needs to change for advanced therapies to reach patients at scale?
Over two days the programme covers emerging science from Swedish and Nordic research groups, regulatory and manufacturing routes that carry it toward the clinic, the trial infrastructure and capability that puts it in front of patients, and the funding and reimbursement models that decide whether it stays there. Throughout it all are the translational journeys behind the field, successes and failures alike, and the patient voices that gives the work purpose.
| Time | Day 1 – Tuesday 1 December, 8:00-18:00 | Topic | Chairs & Co-Chairs | Speakers & Titles |
|---|---|---|---|---|
| 8:00 | Venue Opening & Registration | |||
| 8:45 | Opening Address | |||
| 9:00 | Session 1 Plenary: | From Breakthrough Science to Patient Impact | Matti Sällberg, Karolinska Institute Eva-Karin Gidlund, NorthX Biologics | Di Yu, Uppsala University, Elicera Therapeutics AB: Armed CAR T-cell therapy: from research to clinic Mark Farmery, Anocca AB: From platform to product: Unlocking the solid tumour target space through scalable TCR-T cell therapy development and manufacture Anne-Laure Joly, NeoGap Therapeutics AB: Personalised tumour trained lymphocyte therapy: balancing process standardization while preserving antigen specificity |
| 10:00 | Break | |||
| 10:30 | Session 1 Plenary (Continued): | From Breakthrough Science to Patient Impact | Xiaoqin Wang, AstraZeneca: In vivo CAR T Drug Product Potency Control Strategy – CMC Potency Assay Development Hans Preusting, Mendus: Developing Off-the-Shelf Immunotherapies for Cancer Knut Steffensen, Karolinska ATMP Center: Universities and Hospitals are ATMP innovation hubs driving R&D and economic growth – how do we capitalise on is true potential? | |
| 11:30 | Lunch | |||
12:15 | Conference Sponsor Session with CCRM Nordic | Bridging the Gap: From ATMP Innovation to Scalable Manufacturing | Michael Delahaye, CCRM Nordic | |
| 13:00 | Session 2: | Regulatory Pathways and Accelerated Development in the Nordics and EU | Anna Koptina Gültekin, AI4RA Björn Carlsson, SSI Strategy | Stine Kihl-Plambek, ATMP Denmark: Navigating the European Regulatory Pathway for ATMPs: Starting with the End in Mind Martin Bronislaw Oleksiewicz, DMA & Danish EMA CAT: New approach methodologies and their potential to accelerate ATMP development Björn Carlsson, SSI Strategy: Optimizing agency scientific advice Anna Koptina Gültekin, AI4RA: Transformative Role of AI in Regulatory Writing |
| 14:00 | Break | |||
| 14:30 | Session 2 (Continued): | Regulatory Pathways and Accelerated Development in the Nordics and EU | Alessandro Aiuti, San Raffaele Telethon Institute: Building the ATMP Ecosystem: From Innovation to Patient Impact Panel Discussion: Stine Kihl-Plambek, Martin Bronislaw Oleksiewicz, Alessandro Aiuti Patrick Ginty, VectusBio Consulting | |
| 15:30 | Session 3: | Frontiers in ATMP Discovery and Innovation + Poster Session | Pierfrancesco Pagella, Linköping University Mattias Magnusson, Lund University Johan Flygare, Lund University Fredrik Lanner, Karolinska Institutet Anna Pasetto, Oslo University Hospital | Malin Parmar, Lund University: From Scientific Discovery to Patients: The Making of STEM-PD Selected abstract presentations |
| 16:00 | Break | |||
| 16:30 | Session 3 (Continued): | Frontiers in ATMP Discovery and Innovation | Selected abstract presentations Karl Johan Malmberg, Karolinska Institutet: Thirty-Three Years Chasing the Missing Self | |
| 18:00-Late | After Work + Poster Session | |||
| Time | Day 2 – Wednesday 2 December, 8:30-18:30 | Topic | Chairs & Co-Chairs | Speakers |
|---|---|---|---|---|
| 8:30 | Venue Opening & Registration | |||
| 9:00 | Session 4: | Clinical Advancement and Challenges in ATMP for the Brain | Mats Hellström, Uppsala University Hjalmar Bjartmarz, Skåne University Hospital | Xiuming Liang, Karolinska Institute: Toward Clinical Translation of Extracellular Vesicle-Mediated Genome Editing in the Brain Mats Hellström, Uppsala University: CARMA-02, systemic and loco-regional treatment of primary CNS lymphoma using CD20-targeting CAR-T cells Hjalmar Bjartmarz, Skåne University Hospital: How to surgically deliver ATMPs into the Brain |
| 10:00 | Break | |||
| 10:30 | Session 4 (Continued): | Clinical Advancement and Challenges in ATMP for the Brain | Fredrik Swartling, Uppsala University: AAV SOX-9 gene therapy for Glioma Håkan Widner, Skåne University Hospital: Stem PD | |
| 11:30 | Lunch & Mingle | |||
| 13:00 | Session 5: | From Price Tags to Payment Pathways: Innovation in Europe | Jim Lund, CCRM Nordic | Sara Lowemark, LIF: Securing European Pharmaceutical Innovation Chris Sampson, Tertium Research: Establishing the ROI for a CGT system shift |
| 14:00 | Break | |||
| 14:30 | Session 5 (Continued): | From Price Tags to Payment Pathways: HTA – what is it and what does it do | Dag Larsson, Lif | Niklas Hedberg, TLV: HTA Regulation and European Joint Clinical Assessment Francis Pang, Orchard Tx: Company expectations and experience this far Ingela Hallberg, Nätverket mot cancer: What’s expected from patients’ perspectives Panel Discussion |
| 15:30 | Session 6: | Clinical Translation / Innovation Network and the Patient Impact | Hannah Karlsson, ATMP Uppsala, CGT Sweden NACNET Helena Luning, SweTrial | Hannah Karlsson, ATMP Uppsala, CGT Sweden NACNET Antonia Mueller, Medical University of Vienna: From innovation to patients: mapping the European advanced therapy medicinal product development pipeline Panel Discussion |
| 16:00 | Break | |||
| 16:30 | Session 6 (Continued): | Clinical Translation / Innovation Network and the Patient Impact | Kristina Kannisto, SweTrial Karl-Henrik Grinnemo, AVulotion AB: Preventing Heart Failure with Extracellular Vesicles: From the CAMP Project to Clinical Translation Natasha Bank, ATMP Flemingsberg: Beyond Infrastructure: Building the Culture and Ecosystems That Turn Science into Patient Impact | |
| 18:00 | Closing Adress | |||
The agenda is still taking shape – session names, timing, and other details are subject to change.